Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction.
delphi survey
esophageal adenocarcinoma
gastroesophageal junction carcinoma
neoadjuvant treatment
overall survival
tumor tissue response
Journal
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
ISSN: 1442-2050
Titre abrégé: Dis Esophagus
Pays: United States
ID NLM: 8809160
Informations de publication
Date de publication:
15 Jun 2020
15 Jun 2020
Historique:
received:
23
07
2019
revised:
22
11
2019
accepted:
23
01
2020
pubmed:
7
3
2020
medline:
14
7
2021
entrez:
7
3
2020
Statut:
ppublish
Résumé
Multimodality treatment combining surgery and oncologic treatment has become widely applied in curative treatment of esophageal and gastroesophageal junction adenocarcinoma. There is a need for a standardized tumor regression grade scoring system for clinically relevant effects of neoadjuvant treatment effects. There are numerous tumor regression grading systems in use and there is no international standardization. This review has found nine different international systems currently in use. These systems all differ in detail, which inhibits valid comparisons of results between studies. Tumor regression grading in esophageal and gastroesophageal junction adenocarcinoma needs to be improved and standardized. To achieve this goal, we have invited a significant group of international esophageal and gastroesophageal junction adenocarcinoma pathology experts to perform a structured review in the form of a Delphi process. The aims of the Delphi include specifying the details for the disposal of the surgical specimen and defining the details of, and the reporting from, the agreed histological tumor regression grade system including resected lymph nodes. The second step will be to perform a validation study of the agreed tumor regression grading system to ensure a scientifically robust inter- and intra-observer variability and to incorporate the consented tumor regression grading system in clinical studies to assess its predictive and prognostic role in treatment of esophageal and gastroesophageal junction adenocarcinomas. The ultimate aim of the project is to improve survival in esophageal and gastroesophageal adenocarcinoma by increasing the quality of tumor regression grading, which is a key component in treatment evaluation and future studies of individualized treatment of esophageal cancer.
Identifiants
pubmed: 32141500
pii: 5788233
doi: 10.1093/dote/doaa005
pmc: PMC7273185
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66
pubmed: 11602373
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):115-21
pubmed: 19251379
World J Surg. 2002 May;26(5):584-7
pubmed: 12098049
Nature. 2017 Jan 12;541(7636):169-175
pubmed: 28052061
Lancet. 2012 May 19;379(9829):1887-92
pubmed: 22552194
Lancet Oncol. 2016 Dec;17(12):1697-1708
pubmed: 27776843
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
World J Surg. 2014 Jan;38(1):106-13
pubmed: 24101018
Ann Surg. 2008 Oct;248(4):549-56
pubmed: 18936567
J Surg Oncol. 2006 Sep 15;94(4):307-15
pubmed: 16917878
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Scand J Gastroenterol. 2017 Jun - Jul;52(6-7):647-653
pubmed: 28276825
Ann Surg. 2012 Dec;256(6):1002-7
pubmed: 22968067
Ann Surg. 2013 Nov;258(5):784-92; discussion 792
pubmed: 24045450
Eur J Cancer. 2011 Feb;47(3):354-60
pubmed: 21084184
Chest. 1997 Jun;111(6):1718-23
pubmed: 9187199
Ann Surg. 2008 Aug;248(2):221-6
pubmed: 18650631
J Gastrointest Surg. 2007 Nov;11(11):1384-93; discussion 1393-4
pubmed: 17764019
J Clin Oncol. 2005 Feb 20;23(6):1237-44
pubmed: 15718321
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
J Clin Oncol. 2011 May 1;29(13):1715-21
pubmed: 21444866
Cancer. 2005 Apr 1;103(7):1347-55
pubmed: 15719440
J Thorac Cardiovasc Surg. 2009 Sep;138(3):594-602; discussion 601-2
pubmed: 19698841
Surg Today. 1994;24(5):410-4
pubmed: 8054811
Ann Surg. 2005 Nov;242(5):684-92
pubmed: 16244542
Ann Surg Oncol. 2010 Apr;17(4):1159-67
pubmed: 20140529
Ann Surg Oncol. 2008 Oct;15(10):2894-902
pubmed: 18663531
Ann Thorac Surg. 2010 Nov;90(5):1662-7
pubmed: 20971285
Am J Surg Pathol. 2006 Jan;30(1):28-35
pubmed: 16330939
N Engl J Med. 2008 Jan 3;358(1):36-46
pubmed: 18172173
Hum Pathol. 2019 Feb;84:26-34
pubmed: 30217622
Expert Rev Anticancer Ther. 2018 Apr;18(4):327-338
pubmed: 29431018
Eur J Cardiothorac Surg. 2003 Oct;24(4):631-6; discussion 636-7
pubmed: 14500086
Ann Surg Oncol. 2011 Dec;18(13):3743-54
pubmed: 21556952
Semin Thorac Cardiovasc Surg. 2016 Summer;28(2):549-558
pubmed: 28043475
Int J Surg. 2014;12(6):621-5
pubmed: 24802520
J Thorac Dis. 2017 Jul;9(Suppl 8):S697-S704
pubmed: 28815065
Lancet Oncol. 2007 Mar;8(3):226-34
pubmed: 17329193
BMC Cancer. 2011 May 19;11:181
pubmed: 21595951
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686
Ann Surg Oncol. 2013 Sep;20(9):3009-14
pubmed: 23504143
Histopathology. 2005 Aug;47(2):141-6
pubmed: 16045774